Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Sex-biased clinical presentation and outcomes from COVID-19

Eileen P. Scully 1, Amita Gupta 1, Sabra L. Klein 2,*

1 Department of Medicine, Division of Infectious Diseases, Johns Hopkins University, Baltimore, MD, USA
2 W. Harry Feinstone Department of Molecular Microbiology and Immunology, Johns Hopkins Bloomberg School of Public Health, MD, USA

ARTICLE INFO

Article history:
Received 7 January 2021
Received in revised form 25 February 2021
Accepted 6 March 2021
Available online 1 April 2021

Editor: L. Leibovici

Keywords:
CRP
Inflammation
Pathogenesis
SARS-CoV-2
Sex differences

Around the world, while males and females are equally likely to test positive for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), males are significantly more likely to be hospitalized, to be admitted into intensive care units, and to die from coronavirus disease 2019 (COVID-19) [1,2]. Although globally the proportions of males and females testing positive for SARS-CoV-2 are similar, a number of gender-associated differences—including behaviour (e.g. acceptance of public health measures that limit virus spread) [3], occupation [4], and access to healthcare for testing [5]—contribute to notable regional differences in SARS-CoV-2 exposure between the sexes [6].

Gender differences (i.e. a social construct that defines norms for men and women) are separate from but complementary to biological sex differences that are mediated by sex chromosome complement, differential reproductive tissues, and differential concentrations of sex steroid hormones. The enrichment of the X chromosome for immune response genes [7], combined with the presence of sex steroid hormone receptors on diverse innate and adaptive immune cells, and the presence of hormone response elements in the promoters of numerous immune response genes, can give rise to sex differences in immunity to viruses [8]. Consequently, there are sex differences in immunity to SARS-CoV-2, control of virus replication, development of immunopathologies, and long-term protection [9]. For example, deleterious mutations in X-linked genes (e.g. TLR7) have been linked to worse COVID-19 outcomes in males [10]. Males consistently have greater proinflammatory cytokine production (e.g. IL-6) than females in the context of COVID-19, although it is unclear whether this difference is a marker of sex differences in disease severity [11,12]. Older males with COVID-19 have lower CD8+ T-cell activity (e.g. IFN-γ production and proliferation) [13], but have greater antibody responses [14] than females. The durability of neutralizing antibodies, however, is lower for males than females over time [15].

Consistent with observations of sex differences in inflammation, the paper by Mussini et al. [16] reported that baseline as well as follow-up concentrations of C-reactive protein (CRP) and ferritin were greater in males than in females. This was despite the fact that females were significantly more likely to be obese, a condition which is generally associated with increased inflammation. These male COVID-19 patients also had more respiratory impairment at presentation (i.e. baseline PaO2/FiO2) and were more likely than females to require mechanical ventilation and to die from COVID-19. In linear mixed models, it was CRP that was the greatest mediator of the risk of invasive mechanical ventilation and death from COVID-19 pneumonia.

The population under study in the paper by Mussini et al. [16] included only those patients already meeting a definition of severe disease on presentation; the persistence of sex differences even in this group points to biological mechanisms that underlie differential outcomes in males and females. These data highlight the need to disaggregate and analyse data for sex differences to better understand the pathogenesis of COVID-19 disease. It remains unknown what role CRP has in prospectively predicting sex-specific risk, or whether it should be analysed using different sex-specific cut-offs. Larger datasets are needed to help answer these questions. It will be necessary for future studies to evaluate whether sex differences in inflammatory mediators exist in patients with less-severe COVID-19 from other centres. It will also be equally important for studies of the COVID-19 vaccine to disaggregate data by sex. While vaccine efficacy appears to be similar between the sexes [17],
adverse reactions are more frequently reported by female than male vaccinees, which could provide insight into sex-specific dosing and monitoring of vaccinees.

In summary, the study by Mussini et al. [16] provides evidence that respiratory failure caused by COVID-19 is worse for males than for females, and that inflammatory proteins, including CRP, may serve as biomarkers for severe disease in males.

Transparency declaration

No funding was received for this commentary.

References

[1] GlobalHealth5050. The sex, gender and COVID-19 project. https://globalhealth5050.org/the-sex-gender-and-covid-19-project/. [Accessed 28 December 2020].
[2] Peckham H, de Gruijter NM, Raine C, Radziszewska A, Curtin C, Weederburn LR, et al. Male sex identified by global COVID-19 meta-analysis as a risk factor for death and ITU admission. Nat Commun 2020;11:6317.
[3] Galasso V, Pons V, Profeta P, Becher M, Brouard S, Foucault M. Gender differences in COVID-19 attitudes and behavior: panel evidence from eight countries. Proc Natl Acad Sci USA 2020;117:27285–91.
[4] Wenham C, Smith J, Morgan R, on behalf of theGender and COVID-19 Working Group. COVID-19: the gendered impacts of the outbreak. Lancet 2020;395:846–8.
[5] Ryan NE, El Ayadi AM. A call for a gender-responsive, intersectional approach to address COVID-19. Glob Publ Health 2020;15:1404–12.
[6] Bischof E, Wolfe J, Klein SL. Clinical trials for COVID-19 should include sex as a variable. J Clin Invest 2020;130:3350–2.
[7] Fish EN. The X-files in immunity: sex-based differences predispose immune responses. Nat Rev Immunol 2008;8:737–44.
[8] Klein SL, Flanagan KL. Sex differences in immune responses. Nat Rev Immunol 2016;16:626–38.
[9] Scully EP, Haverfield J, Ursin RL, Tannenbaum C, Klein SL. Considering how biological sex impacts immune responses and COVID-19 outcomes. Nat Rev Immunol 2020;20:442–7.
[10] van der Made CI, Simons A, Schuurs-Hoejmakers J, van den Heuvel G, Mantere T, Koster S, et al. Presence of genetic variants among young men with severe COVID-19. JAMA 2020;324:1–11.
[11] Del Valle DM, Kim-Schulze S, Huang IH, Beckmann ND, Nirenberg S, Wang B, et al. An inflammatory cytokine signature predicts COVID-19 severity and survival. Nat Med 2020;26:1636–43.
[12] Meng Y, Wu P, Lu W, Liu K, Ma K, Huang L, et al. Sex-specific clinical characteristics and prognosis of coronavirus disease-19 infection in Wuhan, China: a retrospective study of 168 severe patients. PLoS Pathog 2020;16:e1008320.
[13] Takahashi T, Ellingson MK, Wong P, Israelow B, Lucas C, Klein J, et al. Sex differences in immune responses that underlie COVID-19 disease outcomes. Nature 2020;588:315–20.
[14] Klein SL, Pokoz A, Park HS, Ursin RL, Shapiro JR, Benner SE, et al. Sex, age, and hospitalization drive antibody responses in a COVID-19 convalescent plasma donor population. J Clin Invest 2020;130:6141–50.
[15] Grzelak L, Velay A, Madec Y, Gallais F, Staropoli I, Schmidt-Mutter C, et al. Sex differences in the decline of neutralizing antibodies to SARS-CoV-2. medRxiv 2020. 11.12.20230466.
[16] Mussini C, Cozzi-Leprri A, Menozzi M, Meschiari M, Franceschini E, Rogati C, et al. Modena Covid-19 Working Group (MoCo19), Office of information and communication technologies of Policlinico di Modena. Better prognosis in females with severe COVID-19 pneumonia: possible role of inflammation as potential mediator. Clin Microbiol Infect 2021;27(8):1137–44. https://doi.org/10.1016/j.cmi.2020.12.010.
[17] Voysey M, Clemens SAC, Madhi SA, Weckx LY, Folegatti PM, Aley PK, et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet 2021;397:99–111.